Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články
PubMed
30087463
DOI
10.1038/s41409-018-0288-0
PII: 10.1038/s41409-018-0288-0
Knihovny.cz E-zdroje
- MeSH
- akutní myeloidní leukemie farmakoterapie mortalita terapie MeSH
- busulfan analogy a deriváty farmakologie terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití MeSH
- příprava pacienta k transplantaci metody MeSH
- senioři MeSH
- transplantace hematopoetických kmenových buněk metody MeSH
- vidarabin analogy a deriváty farmakologie terapeutické užití MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- busulfan MeSH
- fludarabine MeSH Prohlížeč
- treosulfan MeSH Prohlížeč
- vidarabin MeSH
FLAMSA followed by sequential reduced intensity conditioning and treosulfan/fludarabine are frequently used conditioning approaches used in centers of the European Society for Blood and Marrow Transplantation (EBMT) for older patients with acute myeloid leukemia (AML). It is currently unknown whether any of these regimens is superior to the others in terms of disease control and toxicity. Using the Acute Leukemia Working Party/EBMT multicenter registry we compared the outcomes of AML patients 45-65 of age transplanted between the years 2007 and 2016. A total of 629 patients were included in the analysis: 281 in the Treo/Flu group, 203 in the FLAMSA/TBI group, and 145 in the FLAMSA/Busulfan group. In multivariate analysis, FLAMSA/TBI conditioned patients had a decreased risk of relapse (hazard ratio (HR) = 0.43; 95% confidence interval (CI), 0.25-0.75; p = 0.002) and superior leukemia-free survival (HR = 0.67; 95% CI, 0.45-0.98; p = 0.042) compared to Treo/Flu conditioned patients. Rates of acute graft-versus-host disease (GVHD) were significantly higher in the FLAMSA/TBI group compared to the Treo/Flu group (HR = 2.004; 95% CI, 1.09-3.67; p = 0.024). Overall survival, non-relapse mortality, and chronic GVHD were not significantly impacted by the specific regimen used. The choice of either FLAMSA/TBI, FLAMSA/Bu, or Treo/Flu results in no major impact on survival of older AML patients.
Center Hospitalier Lyon Sud Pavillon Marcel Bérard Bat 1G Service Hematologie Lyon France
Department of Hematology and Stem Cell Transplant Kings College Hospital London London UK
Department of Hematology and Stem Cell Transplant Vanderbilt University Nashville TN USA
Department of Internal Medicine BMT Unit University of Saarland University Hospital Homburg Germany
Department of Internal Medicine Hematooncology University Hospital Brno Brno Czech Republic
Deutsche Klinik fuer diagnostik KMT Zentrum Weisbaden Germany
EBMT Paris Office CEREST TC Department of Hematology Saint Antoine Hospital Paris France
Hematology Division Chaim Sheba Medical Center Tel Hashomer Tel Aviv University Tel Aviv Israel
Stem Cell Transplantation Unit HUCH Comprehensive Cancer Center Helsinki Finland
Citace poskytuje Crossref.org
